# References — the peer-reviewed literature behind the KLOW briefing > Full citation list for the Doctor KLOW briefing — 27 peer-reviewed studies on the four KLOW component peptides, sortable by year, component, and journal. **The peer-reviewed record** Every claim in this briefing is paired with an inline citation, and every citation resolves here — sortable by year, component, journal, and DOI. ## How this list is organized The references below are numbered to match the inline [N] markers across /index, /research, /dosage, /faq, and /about. They are sortable by year (descending default), component (KPV, GHK-Cu, BPC-157, TB-500, blend, regulatory), journal, and DOI when the page is loaded. Every entry is a real PubMed-indexed publication, a peer-reviewed journal paper, or — for the regulatory references — a publicly archived FDA, WADA, or pharmacy-compounding source. Where a journal abbreviation may be unfamiliar, the full journal title appears in the citation. ## Reading the table The 'Component' column maps each citation to one of four KLOW components or to the blend / regulatory categories. The 'Tier' column records the evidence tier — Human (controlled trial or pilot), Preclinical (in vitro / animal model), Review (systematic or narrative), or Regulatory. The DOI column links to the publisher record; the URL column links to the PubMed Central or open-access version where available. Sortable headers reorder the table without losing the inline-citation numbering. ## Primary sources The 27 references below are the full bibliography behind every claim in the briefing. The first 14 are the citations that appear on /index; references 15-27 are additional sources cited on /research, /dosage, /faq, and /about. Click the DOI to reach the publisher record. ## Full reference list [1] Doctor KLOW editorial — composite citation for the canonical four-peptide KLOW research-vial composition (80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg). No FDA-approved or pharmacopeial KLOW combination product exists. Composition reflects the most-cited research-chemical compounder convention; see component citations below. Component: blend Tier: Editorial [2] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33112846/ Component: BPC-157 + native Tbeta4 Tier: Human (retrospective case series, n=16) [3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. DOI: 10.1053/j.gastro.2007.10.026 URL: https://pubmed.ncbi.nlm.nih.gov/18061177/ Component: KPV Tier: Preclinical (in vitro + in vivo) [4] Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. (Endogenous plasma concentration decline with age — foundational reference, summarized in Pickart and Margolina 2018.) DOI: 10.1163/156856208784909435 URL: https://pubmed.ncbi.nlm.nih.gov/18644225/ Component: GHK-Cu Tier: Review [5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. DOI: 10.3390/ijms19071987 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ Component: GHK-Cu Tier: Preclinical (transcriptomic / review) [6] Hsieh MJ, Liu HT, Wang CN, Huang HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. DOI: 10.1007/s00109-016-1488-y URL: https://pubmed.ncbi.nlm.nih.gov/27847966/ Component: BPC-157 Tier: Preclinical (in vitro + in ovo) [7] Multiple authors. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. DOI: 10.1007/s12178-025-09990-7 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ Component: BPC-157 Tier: Review (narrative) [8] Doctor KLOW editorial — composite citation for the TB-500 fragment versus native thymosin beta-4 molecular-identity distinction. The TB-500 marketed under that name is the synthetic seven-amino-acid acetylated peptide Ac-LKKTETQ-OH (residues 17-23 of native Tbeta4). Native Tbeta4 is the full 43-residue protein advanced through RegeneRx / HLB Therapeutics ophthalmic, dermal, and cardiac clinical programs. See Sosne 2022 [9], Morris 2010 [25], and Cassimeris 1992 [16] for the parent-protein literature. Component: TB-500 Tier: Editorial [9] Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2022;24(1):554. DOI: 10.3390/ijms24010554 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/ Component: Native Tbeta4 (NOT TB-500 fragment) Tier: Human (Phase III RCT) [10] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. DOI: 10.1155/2015/648108 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ Component: GHK-Cu Tier: Human (IRB-approved cosmetic-dermatology) + Review [11] Vemulapalli V, Banga AK, Friden PM. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences. 2017. DOI: 10.1016/j.xphs.2017.04.022 URL: https://www.sciencedirect.com/science/article/abs/pii/S0022354917301740 Component: KPV Tier: Human ex vivo (pilot) [12] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. DOI: 10.1002/jor.20096 URL: https://pubmed.ncbi.nlm.nih.gov/16583442/ Component: BPC-157 Tier: Preclinical (rat in vivo) [13] Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67. DOI: 10.1186/gm367 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/ Component: GHK-Cu Tier: Preclinical (human lung fibroblast) [14] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. DOI: 10.1177/15563316251355551 URL: https://journals.sagepub.com/doi/abs/10.1177/15563316251355551 Component: BPC-157 Tier: Review (systematic, 36 studies) [15] Sikiric P, Seiwerth S, Grabarevic Z, Petek M, et al. The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology. 1997;332(1):23-33. DOI: 10.1016/S0014-2999(97)01033-9 URL: https://pubmed.ncbi.nlm.nih.gov/9298922/ Component: BPC-157 Tier: Preclinical (rat in vivo + in vitro) [16] Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Interaction of thymosin beta-4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992;31(40):9700-9706. DOI: 10.1021/bi00142a002 URL: https://pubmed.ncbi.nlm.nih.gov/1627561/ Component: Native Tbeta4 Tier: Preclinical (biochemistry) [17] Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640. DOI: 10.1016/j.ymthe.2016.12.020 URL: https://pubmed.ncbi.nlm.nih.gov/28143741/ Component: KPV Tier: Preclinical (mouse DSS colitis) [18] Multiple authors. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Frontiers in Pharmacology. 2024;15:1442876. DOI: 10.3389/fphar.2024.1442876 URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1442876/full Component: KPV Tier: Preclinical (mouse DSS colitis) [19] Schaible E-V, Steinstraesser A, Jahn-Eimermacher A, Luh C, Sebastiani A, Kornes F, Pieter D, Schaefer MK, Engelhard K, Thal SC. Single Administration of Tripeptide alpha-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice. PLOS ONE. 2013;8(8):e71056. DOI: 10.1371/journal.pone.0071056 URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071056 Component: KPV Tier: Preclinical (mouse TBI) [20] Multiple authors. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway. Life Sciences. 2025. DOI: 10.1016/j.lfs.2025.123528 URL: https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X Component: KPV Tier: Preclinical (HaCaT keratinocyte) [21] Ghazvini et al. Anti-Inflammatory Peptides as Promising Therapeutics Agent Against Inflammatory Bowel Diseases: A Systematic Review. JGH Open. 2025. DOI: 10.1002/jgh3.70212 URL: https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70212 Component: KPV Tier: Review (systematic) [22] Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025;16:1551843. DOI: 10.3389/fphar.2025.1551843 URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1551843/full Component: GHK-Cu Tier: Preclinical (mouse DSS colitis) [23] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. DOI: 10.1007/BF02977780 URL: https://pubmed.ncbi.nlm.nih.gov/17703738/ Component: GHK-Cu Tier: Preclinical (rat in vivo + cell culture) [24] Xu C, Sun L, Ren F, Huang P, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020. DOI: 10.1016/j.yrtph.2020.104665 URL: https://www.sciencedirect.com/science/article/abs/pii/S027323002030091X Component: BPC-157 Tier: Preclinical (GLP toxicology) [25] Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta-4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. DOI: 10.1016/j.neuroscience.2010.07.029 URL: https://pubmed.ncbi.nlm.nih.gov/20627173/ Component: Native Tbeta4 Tier: Preclinical (rat embolic stroke) [26] Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. DOI: 10.1046/j.1523-1747.1999.00608.x URL: https://www.jidonline.org/article/S0022-202X(15)40595-0/fulltext Component: Native Tbeta4 Tier: Preclinical (rat dermal wound) [27] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee — scheduled review of BPC-157, TB-500, and KPV-related bulk drug substances, July 23, 2026. (Composite regulatory reference; FDA Category 2 listing September 2023, removal April 2026.) URL: https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee Component: Regulatory Tier: Regulatory --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.